Arimidex: Compliance and Arthralgias in Clinical Therapy (COMPACT): An in Practice Assessment of Arthralgias and Related Costs as Well as Compliance in the First Year of Anastrozole Therapy
The patient population will include postmenopausal women with hormone-receptor positive
primary breast cancer scheduled for adjuvant upfront endocrine treatment with anastrozole or
following two to three years of tamoxifen treatment ("switch") according to the current SmPC
(Appendix C). Patients will have taken anastrozole for at least three months and not more
than six months before the start of the study.
Observational Model: Case-Only, Time Perspective: Prospective
Assessment of arthralgia scores and patients` compliance within the first year of anastrozole treatment, stratified by upfront and switch therapy as well as assessment of the relationship between compliance and arthralgia scores.
Germany: Federal Institute for Drugs and Medical Devices